Corvus Pharmaceuticals (CRVS) Times Interest Earned (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Times Interest Earned came in at -$16.1 in Q1 2026, up 8.15% year-on-year from -$14.89 in Q1 2025, and up 13.8% quarter-over-quarter from -$18.68 in Q3 2025.
Corvus Pharmaceuticals (CRVS) Times Interest Earned (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Times Interest Earned history runs 12 years deep, the most recent figure standing at -$16.1 for Q1 2026.
- On a quarterly basis, Times Interest Earned rose 8.15% year-over-year to -$16.1 in Q1 2026; TTM through Mar 2026 was -$49.38, a 4.81% increase from a year earlier, with the FY2023 full-year figure at -$0.28, up 98.53% from the prior year.
- Times Interest Earned rose to -$16.1 in Q1 2026 per CRVS's latest filing, from -$18.68 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$5.82 in Q1 2024 and bottomed at -$59.65 in Q2 2025.
- The 5-year median for Times Interest Earned is -$16.1 (2026), against an average of -$18.17.
- Across the five-year window, Times Interest Earned soared 59.39% in 2024 and sank 620.64% in 2025, its largest moves.
- Year by year, Times Interest Earned stood at -$13.18 in 2022, then rose by 6.97% to -$12.26 in 2023, then plunged by 65.32% to -$20.27 in 2024, then rose by 7.83% to -$18.68 in 2025, then grew by 13.8% to -$16.1 in 2026.
- Per Business Quant, the three latest CRVS Times Interest Earned figures stand at -$16.1 (Q1 2026), -$18.68 (Q3 2025), and -$59.65 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | -16.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.10 |
| Sep 30, 2025 | -18.68 |
| Jun 30, 2025 | -59.65 |
| Mar 31, 2025 | -17.53 |
| Sep 30, 2024 | -20.27 |
| Jun 30, 2024 | -8.28 |
| Mar 31, 2024 | -5.82 |
| Dec 31, 2023 | -12.26 |
| Sep 30, 2023 | -12.11 |
| Jun 30, 2023 | -12.22 |
| Mar 31, 2023 | -14.32 |
| Dec 31, 2022 | -13.18 |
| Sep 30, 2022 | -28.81 |
| Jun 30, 2022 | -16.20 |
| Mar 31, 2022 | -17.12 |
| Dec 31, 2021 | -16.81 |
| Sep 30, 2021 | -21.91 |
| Jun 30, 2021 | -27.34 |
| Mar 31, 2021 | -27.80 |
| Dec 31, 2020 | -26.41 |